Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Serina Therapeutics (SER) Shares Outstanding (Diluted Average) (2021 - 2025)

Serina Therapeutics (SER) has disclosed Shares Outstanding (Diluted Average) for 5 consecutive years, with $10.2 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 38.47% to $10.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.2 million through Dec 2025, up 38.47% year-over-year, with the annual reading at $10.2 million for FY2025, 38.47% up from the prior year.
  • Shares Outstanding (Diluted Average) hit $10.2 million in Q4 2025 for Serina Therapeutics, up from $10.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $37.9 million in Q1 2022 to a low of $1079.0 in Q4 2022.
  • Historically, Shares Outstanding (Diluted Average) has averaged $9.8 million across 5 years, with a median of $7.6 million in 2023.
  • Biggest YoY gain for Shares Outstanding (Diluted Average) was 681178.96% in 2023; the steepest drop was 80.41% in 2023.
  • Year by year, Shares Outstanding (Diluted Average) stood at $37.7 million in 2021, then crashed by 100.0% to $1079.0 in 2022, then surged by 681178.96% to $7.4 million in 2023, then grew by 0.11% to $7.4 million in 2024, then skyrocketed by 38.47% to $10.2 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for SER at $10.2 million in Q4 2025, $10.0 million in Q3 2025, and $10.0 million in Q2 2025.